CALGARY, June 9, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces it will be hosting a corporate update via webcast on Monday, June 13, 2016 at 11:00 am MT / 1:00 pm ET. Mr. Donald McCaffrey, President and Chief Executive Officer will present an update and overview of recent activities.
To join the webcast, please visit: http://services.choruscall.ca/links/resverlogix20160613.html
To call-in, please dial:
Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Date: Monday, June 13, 2016
Time: 11:00 am MT/1:00 pm ET
Duration: ~30 minutes
A presentation will accompany and be available via the webcast. Alternatively, the presentation will be made available immediately prior to the conference call start time of 11:00am MT on the Company's website at: http://www.resverlogix.com/media/events.html#.V1mWrrsrJD8
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
For further information please contact:
Email: [email protected]
SOURCE Resverlogix Corp.